Valiant Laboratories Limited, a chemical manufacturing company, has reported a profit for the second quarter, while also addressing a recent fine imposed by stock exchanges for delayed disclosure of a committee meeting.

Financial Performance

For the quarter ended September 30, Valiant Laboratories reported a consolidated net profit of ₹20.01 crore. The company's total income for the quarter stood at ₹470.68 crore, with revenue from operations at ₹462.02 crore.

Key financial highlights for Q2 (consolidated):

The company's board of directors reviewed and approved these results in their meeting held on November 11.

Stock Exchange Fine

Valiant Laboratories also addressed a fine imposed by BSE Limited and National Stock Exchange for non-compliance with listing regulations. The company was penalized for delayed prior intimation of a Rights Issue Committee Meeting held on July 15.

Key points regarding the fine:

• Both stock exchanges imposed fines of ₹2,11,800 each (inclusive of GST)
• The company paid the fines on August 20, within prescribed timelines
• The Board stated that the non-compliance was not deliberate and resulted from practical challenges in scheduling the committee meeting
• The Rights Issue Committee meeting was scheduled promptly after receiving in-principle approvals from stock exchanges (NSE approval on July 11, and BSE approval on July 14)

The company's board considers the matter fully complied with and closed.

Rights Issue Details

The Rights Issue Committee was authorized to determine key terms including:

• Issue price
• Record date
• Entitlement ratio

These decisions were made in the committee meeting that led to the delayed disclosure.

Management Commentary

Santosh Shantilal Vora, Managing Director of Valiant Laboratories, stated, "While we regret the delay in disclosure that led to the fine, we are pleased with our financial performance this quarter. Our focus remains on maintaining transparency and compliance while driving growth in our chemical manufacturing business."

Valiant Laboratories continues to operate as a single-segment company engaged in the manufacturing of chemicals. The company's financial results will be available on its website ( www.valiantlab.in ) and on the websites of BSE Limited and NSE.

As the chemical sector navigates through various market challenges, Valiant Laboratories' performance in the coming quarters will be closely watched by investors and industry analysts alike.

Valiant Laboratories Limited has announced that the funds raised through its rights issue have been appropriately utilized, according to the monitoring agency report for the quarter ended September 30, 2025. The report, prepared by India Ratings and Research Private Limited, confirms no deviation from the stated objectives of the rights issue.

Rights Issue Details

The company raised funds through a rights issue of 1,08,62,500 equity shares at INR 75 per share, with a face value of INR 10 each. The total amount raised was INR 8,146.88 lakhs.

Fund Utilization

The proceeds from the rights issue were utilized as follows:

Unutilized Funds

As of the reporting date, INR 270.00 lakhs of the raised funds remain unutilized. These funds have been deployed in fixed deposits with banks.

Corporate Governance

The monitoring agency report was reviewed by the Audit Committee and Board of Directors of Valiant Laboratories Limited, demonstrating the company's commitment to transparency and proper fund management.

General Corporate Purposes Breakdown

The funds allocated for general corporate purposes were utilized as follows:

It's worth noting that INR 880.83 lakhs of the vendor payments were made to Valiant Organics Limited, the ultimate holding company, for the purchase of raw materials.

Conclusion

The monitoring agency report confirms that Valiant Laboratories Limited has adhered to the stated objectives of its rights issue, with no deviations reported. This demonstrates the company's commitment to responsible financial management and transparency in its operations.